Projects per year
Personal profile
Headline
Fingerprint
- 1 Similar Profiles
Network
-
-
NMDA receptor modulation for hyperarousal in PTSD
NATIONAL INSTITUTE OF MENTAL HEALTH
21/09/16 → 31/01/21
Project: Research
-
KETAMINE FOR TREATMENT RESISTANT LATE-LIFE DEPRESSION
U.S. Department of Veterans Affairs
1/10/15 → 30/09/20
Project: Research
-
KETAMINE FOR TREATMENT RESISTANT LATE-LIFE DEPRESSION
U.S. Department of Veterans Affairs
1/10/15 → 31/03/21
Project: Research
-
KETAMINE FOR TREATMENT RESISTANT LATE-LIFE DEPRESSION
U.S. Department of Veterans Affairs
1/10/15 → 30/09/20
Project: Research
-
A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression
Tamman, A., Anand, A. & Mathew, S. J., 2022, In: Expert Opinion on Drug Safety. 21, 6, p. 745-759 15 p.Research output: Contribution to journal › Review article › peer-review
1 Scopus citations -
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial
Price, R. B., Spotts, C., Panny, B., Griffo, A., Degutis, M., Cruz, N., Bell, E., Do-Nguyen, K., Wallace, M. L., Mathew, S. J. & Howland, R. H., Dec 2022, In: American Journal of Psychiatry. 179, 12, p. 959-968 10 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
A Novel Approach to Link Genetics and Human MRI Identifies AKAP7-Dependent Subicular/Prefrontal Functional Connectivity as Altered in Suicidality
Poblete, G., Nguyen, T., Gosnell, S., Sofela, O., Patriquin, M., Mathew, S. J., Swann, A., Nielsen, D. A., Kosten, T. R. & Salas, R., Mar 2022, In: Chronic Stress. 6Research output: Contribution to journal › Article › peer-review
Open Access -
An Update on Community Ketamine Practices
O'Brien, B., Wilkinson, S. T. & Mathew, S. J., 1 May 2022, In: American Journal of Psychiatry. 179, 5, p. 393-394 2 p.Research output: Contribution to journal › Letter › peer-review
3 Scopus citations -
A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine
Bloomfield-Clagett, B., Ballard, E. D., Greenstein, D. K., Wilkinson, S. T., Grunebaum, M. F., Murrough, J. W., Mathew, S. J., Phillips, J. L., Fava, M., Sanacora, G. & Zarate, C. A., 25 Oct 2022, In: International Journal of Neuropsychopharmacology. 25, 10, p. 827-838 12 p.Research output: Contribution to journal › Article › peer-review
Open Access
Press / Media
-
Douglas Pharmaceuticals Announces Formation Of Clinical Advisory Board For Lead Program R-107
26/01/23
1 item of Media coverage
Press/Media
-
Douglas Pharmaceuticals Announces Formation of Clinical Advisory Board for Lead Program R-107
26/01/23
60 items of Media coverage
Press/Media
-
Ketamine lifts depression longer with positive feedback : Shots
31/10/22
1 item of Media coverage
Press/Media
-
Smiling faces might help the drug ketamine keep depression at bay
31/10/22
93 items of Media coverage
Press/Media